Dayton Misfeldt is an Investment Partner at Bay City Capital and has been with the firm since May 2000. Mr. Misfeldt focuses on biopharmaceutical investment opportunities, and has been involved in a number of investments, including MAP Pharmaceuticals, Oculex Pharmaceuticals and Pharmion Corporation. Mr. Misfeldt is a member of the boards of directors of Aciex and Sunesis Pharmaceuticals, and participates as an observer on the board of directors of Presidio Pharmaceuticals. Prior to joining Bay City Capital, Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. He also worked as a Project Manager at LifeScience Economics. Mr. Misfeldt received a BA in Economics from the University of California, San Diego.